Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531 | 0.97 | LOXL2 (0.58) | LOXL2CYP2A6GSK3BMAOBCYP19A1 | |
| SCHEMBL3229956 | 0.95 | LOXL2 (0.56) | LOXL2CYP2A6GSK3BMAOBCYP19A1 | |
| SCHEMBL1078454 | 0.91 | LOXL2 (0.52) | LOXL2CYP2A6GSK3BMAOBCYP19A1 | |
| SCHEMBL10929655 | 0.85 | LOXL2 (0.47) | LOXL2CYP2A6GSK3BMAOBCYP19A1 | |
| SCHEMBL450762 | 0.85 | KIF11 (0.47) | LOXL2CYP2A6GSK3BMAOBCYP19A1 | |
| SCHEMBL10929666 | 0.85 | LOXL2 (0.47) | LOXL2CYP2A6GSK3BMAOBCYP19A1 | |
| SCHEMBL3264554 | 0.85 | PARP15 (0.49) | LOXL2CYP2A6GSK3BMAOBCYP19A1 | |
| SCHEMBL507651 | 0.82 | GSK3B (0.59) | LOXL2CYP2A6GSK3BALDH1A1CA2 | |
| SCHEMBL10925694 | 0.82 | MAOB (0.68) | MAOBCYP19A1MAOA | |
| SCHEMBL9432333 | 0.80 | MAOB (0.46) | LOXL2CYP2A6GSK3BMAOBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101184749-B | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORP | 2012-12-05 | — | — | CN | disclosed |
| CN-101291940-B | Highly reactive zinc form, method for the production thereof and use of the highly reactive zinc form | CHEMETALL GMBH | 2012-05-30 | — | — | CN | disclosed |
| CN-101291940-A | Highly reactive zinc form, method for the production thereof and use of the highly reactive zinc form | CHEMETALL GMBH (DE) | 2008-10-22 | — | — | CN | disclosed |
| CN-101184749-A | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORP (US) | 2008-05-21 | — | — | CN | disclosed |
| US-7256203-B2 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1565458-A2 | DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004050018-A2 | DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-06-17 | — | — | WO | disclosed |
| US-5691347-A | ANGIOTENSIN II INHIBITORS AND VASOCONSTRICTION | ROUSSEL UCLAF (FR) | 1997-11-25 | — | — | US | disclosed |
| US-5650414-A | PYRAZOLOPYRIDINES OR IMIDAZOLOPYRIDINES | ROUSSEL UCLAF (FR) | 1997-07-22 | — | — | US | disclosed |
| US-5478938-A | Antagonists for angiotensin II receptors; hypotensive, cardiotonic agents; cognitive activators | ROUSSEL UCLAF (FR) | 1995-12-26 | — | — | US | disclosed |
| US-5420138-A | Antivasoconstriction compounds and cardiovascular disorders | ROUSSEL-UCLAF (FR) | 1995-05-30 | — | — | US | disclosed |
| US-5324839-A | Hypotensive agents, gastrointestinal and urogenital disorders | ROUSSEL-UCLAF (FR) | 1994-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | NR0B1, NR2C2, DECR1 | LOXL2 692/4885CYP2A6 512/4885GSK3B 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.